Background: As the potential for cancer therapy-related cardiac dysfunction is increasingly recognized, there is a need for the standardization of echocardiographic measurements and cut points to guide treatment. The aim of this study was to determine the reproducibility of cardiac safety assessments across two academic echocardiography core laboratories (ECLs) at the University of Pennsylvania and the Duke Clinical Research Institute.
echocardiographic results. 3 In clinical practice, variability of conventional echocardiographic parameters of left ventricular (LV) function (i.e., LV ejection fraction [LVEF] ) can extend across treatment eligibility thresholds and affect critical decisions regarding cancer therapy. 4 In cancer trials, clinical LVEF data from site echocardiography laboratories are often used to determine study eligibility and evaluate the cardiac consequences of novel cancer therapies, 5, 6 although reproducibility of results across clinical sites is rarely reported. Echocardiographic parameters that assess cardiac mechanics, including myocardial deformation and ventriculararterial coupling, may improve sensitivity for early CTRCD beyond LVEF. 2 However, data in patients with cancer are predominantly derived from single-center studies 7 that may not account for factors recognized to potentially diminish measurement reproducibility. 8 As cardio-oncology progresses toward larger clinical trials, standard echocardiographic measurements and thresholds for treatment, with validated reproducibility of such measures, are vital. Multicenter cardiovascular clinical trials generally use echocardiography core laboratories (ECLs) to provide expertise and consistency for image acquisition and measurements as well as for assessments of imaging eligibility criteria and safety end points. In this regard, ECLs can reduce variability of imaging data and ensure the validity of study results. [9] [10] [11] [12] Cardio-oncology studies have used ECLs, 13 but the practice is not widespread.
Against this background, the National Cancer Institute Division of Cancer Prevention awarded substudies of the PREDICT MDA 2007 0914 (ClinicalTrials.gov identifier NCT01032278) and SCUSF 0806 (ClinicalTrials.gov identifier NCT01009918) trials for the central review of echocardiograms to ECLs at the University of Pennsylvania (Penn) and the Duke Clinical Research Institute (DCRI), respectively. As a condition of the awards, the ECLs were instructed to collaborate with the potential goal of pooling echocardiographic data from the trials. To determine the feasibility of pooling the data, as well as the impact of central echocardiography review in cardio-oncology clinical trials, the ECLs at Penn and DCRI aimed to (1) determine the reproducibility of echocardiographic assessments in cardio-oncology within and across two academic ECLs, (2) identify sources of variability and corrective solutions, and (3) propose recommendations for echocardiographic research in the detection and monitoring of CTRCD, with potential implications for clinical care.
METHODS

Penn and DCRI ECL Group Reads
To align data collection elements, the Penn and DCRI ECLs reviewed two-dimensional (2D) and Doppler echocardiographic parameters of cardiac size and systolic and diastolic function relevant to clinical cardiovascular outcomes in patients with cancer. 13, 14 A harmonization process between ECLs ensued. Sonographers and principal investigators at both ECLs conducted serial calls and multiple Web-conference group reads from October 2013 to March 2014 to share standard operating procedures, review sample echocardiograms, and align ECL perspectives on image quality, border selection, and tracing conventions. Group readings illustrated differences between ECLs on tracing conventions for certain parameters. These included nonconsensus on the angle of the minor axis for LV internal dimensions (e.g., parallel to mitral valve plane vs perpendicular to the LV long axis) and LVendocardial border definitions (e.g., depth of exclusion of trabeculae) during measurements of LV internal dimensions ( Figure 1 ) and volumes (Figure 2 ), respectively. Harmonization efforts were aimed at achieving consensus on the application of measurement conventions outlined in national guidelines recommendations 2, 15, 16 and culminated in the development of consensus reading instructions (please see the Online Appendix, available at www.onlinejase.com) as well as a common comprehensive case report form across ECLs.
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Echocardiographic Acquisition and Creation of Analysis Repository
After developing consensus reading instructions, each ECL contributed echocardiograms for reproducibility analyses. A total of 25 patient echocardiograms were selected from transthoracic echocardiograms previously acquired at both institutions from patients who had completed treatment with potentially cardiotoxic anticancer agents (i.e., doxorubicin with or without trastuzumab) for breast cancer. More detailed clinical data were not made available, as each ECL was blinded to patient characteristics. Selected echocardiograms were required to have visible LV endocardium unobscured by undergaining or artifact and no significant apical foreshortening in 2D acquisitions. Echocardiograms were obtained by dedicated sonographer teams in the Intersocietal Accreditation Commission clinical laboratories at both institutions. All images were acquired using Vivid 7 or E9 machines (GE Healthcare, Milwaukee, WI) at 60 to 90 frames/ sec and digitally archived at the acquisition frame rate. Digital echocardiographic images were deidentified and transferred in standard Digital Imaging and Communications in Medicine format to TomTec (TomTec Imaging Systems, Unterschleissheim, Germany) and DigiView (Digisonics, Houston, TX) analysis workstations at the Penn and DCRI ECLs, respectively. Both ECLs used TomTec 2D Cardiac Performance Analysis version 1.1 for strain analysis.
Measurement of Echocardiography Parameters
After image transfer, measurements of echocardiography parameters were assigned to two readers at each ECL (n = 4 total readers). Readers included three highly experienced research sonographers and a cardiologist with level III certification in echocardiography. Each reader independently analyzed two uniquely identified copies of the 25 patient echocardiograms and recorded 50 measurement results per analyzed parameter. Each result was treated independently (i.e., no averaging within or between readers).
At laboratory A, LV volumes and strain were measured by a single reader; Doppler parameters (i.e., velocities and timing intervals) were measured by a separate reader, according to reader expertise and existent laboratory practices. At laboratory B, each reader measured every parameter. The measurement results generated per echocardiogram by the readers in each ECL are depicted in more detail in Figure 3A . 
Intra-and Interlaboratory Reproducibility Testing
Intra-and interlaboratory reproducibility was evaluated by pairwise comparisons of all possible measurement differences (interpretative variability) among all readers for selected echocardiographic parameters, as described below. 21 For each of the 25 patient echocardiograms, there were four pairwise comparisons of measurement results between the two readers at laboratory B ( Figure 3B ) and eight pairwise comparisons of measurement results between the reader at laboratory A and two readers at laboratory B ( Figure 3C ) on any selected parameter.
The ''acceptable difference,'' or limit of measurement variability, for each parameter served as a benchmark for reproducibility. The intraand interreader acceptable differences were defined prospectively on the basis of literature review of studies with reproducibility data for LV volumes and LVEF, 22 mitral inflow velocities, 23, 24 global longitudinal strain (GLS), 25 and R-wave flow onset and flow end times. 26 All acceptable differences are expressed in absolute terms (Table 1) .
After readers completed the echocardiographic interpretations, result reports were generated, and intra-and interreader pairwise comparisons were displayed in tables and illustrated in dot-plot graphs. Paired measurements with differences exceeding the prespecified acceptable differences (outliers) were reviewed in a group read. If reproducibility between readers was not acceptable for any echocardiographic parameter(s), a process of revisiting image analysis instructions, retraining and retesting ensued.
Retraining and Retesting
Retraining involved Web conference-based sessions among all readers. Review of individual statistical results guided the retraining process by illustrating the extent and direction of outlier pairs. Open discussion among readers helped identify the source(s) of interpretation and/or measurement error(s). Illustrative case examples and the consensus reading instructions were discussed and revised to promote uniformity of interpretation and help eliminate individual idiosyncrasies. After retraining, all readers reinterpreted the 25 echocardiograms twice for selected parameters with unacceptable reproducibility on initial testing, and reproducibility was reevaluated.
Statistical Analysis
Specific standards or a universally preferred index does not exist for assessing intrareader and interreader reproducibility in ECLs; therefore, multiple statistical approaches for assessing reproducibility were considered. 22 The coverage probability (CP) method was selected given its desirable characteristics as an agreement index in the ECL setting, including its computational simplicity, rapid identification of group and individual reader variability and specific disagreements for review and retraining, and broad applicability to patient populations and continuous and categorical variables. 21 CP is the probability that the difference between any two measurements of a parameter on the same echocardiogram are within a prespecified acceptable difference. 21 Specifically, all possible interreader comparisons were examined to determine whether the measurement difference between paired readers was within the prespecified acceptable difference. The nonparametric approach was used to obtain the estimate of CP. The estimate of CP is the proportion of the number of pairwise interreader comparisons within the acceptable difference divided by the number of all possible pairwise comparisons. The higher the CP, the better the reproducibility. Perfect reproducibility corresponded to 100% CP (i.e., CP = 1.00), indicating that all measurements were within the prespecified acceptable difference for that parameter.
The prespecified acceptable differences and the cut point for the CP determine the standard for acceptable reproducibility. In this study, the cut point for the estimated CP was set at 0.80 on the basis of previous studies assessing reproducibility in an ECL setting. 22, 27 Reproducibility was considered acceptable if $80% of all possible pairwise comparisons were within the prespecified acceptable difference for each parameter. Additionally, all pairwise comparisons (100% or CP = 1.00) were required to be within twice the acceptable difference. To easily visualize the reproducibility data and rapidly identify outlier pairs, the results of the CP analysis were displayed graphically for continuous parameters. Statistical analyses were performed using SAS version 9.2 (SAS Institute, Cary, NC).
RESULTS
On the initial testing, there was robust reproducibility within each ECL. Intrareader reproducibility was acceptable (CP $ 0.80) for the a priori defined acceptable difference for all parameters on the basis of analysis of 225 pairwise comparisons (25 for each of the nine parameters) for each reader. All readers achieved a CP of 1.00 for twice the acceptable difference for all parameters except one reader for mitral valve A peak velocity (CP = 0.960). Interreader reproducibility between two readers at laboratory B demonstrated acceptable reproducibility for all parameters except mitral E velocity (CP = 0.770) and mitral A velocity (CP = 0.770) on the basis of analysis of 900 pairwise comparisons (100 for each of nine parameters). Reproducibility performance results within each ECL (i.e., intrareader CPs for all readers at both ECLs and interreader CPs at laboratory B) are shown in Table 2 .
Reproducibility performance results between ECLs are shown in Table 3 . Analysis of 1,800 pairwise comparisons (200 for each of nine parameters) among three readers (for any given parameter) across both ECLs demonstrated acceptable interlaboratory reproducibility for all parameters except calculated LVEF (CP = 0.675), mitral E velocity (CP = 0.715), and mitral A velocity (CP = 0.760). Measurements of GLS in the apical four-chamber view (GLS 4CH ) bordered acceptable reproducibility (CP = 0.805).
Intra-and interreader comparisons for parameters of LV structure and systolic function are illustrated in dot plots, which indicate the direction and absolute magnitude of the measurement differences within a single reader or between pairs of readers for each echocardiogram. Within-ECL comparisons are illustrated in
HIGHLIGHTS
Standardizing echocardiography measurements that guide treatment decisions in cancer is needed. The authors assessed the reproducibility of echocardiographic measurements in cancer across two echocardiography core laboratories. There was robust reproducibility within each laboratory but differences between laboratories. Interlaboratory reproducibility for LVEF and GLS was less concordant. Comparing small changes in LVEF and GLS across laboratories should be done cautiously.
Figures 4 and 5. The differences for calculated LVEF measurements by a single reader at laboratory A ( Figure 4A ) and between two readers at laboratory B ( Figure 4B ) were typically within 5% and all were within 10%. The differences for GLS 4CH measurements exceeded 4% (the prespecified minimum acceptable threshold) on only two echocardiograms at each ECL ( Figures 5A and 5B ). Between-ECL comparisons for LV volumes were acceptably reproducible; however, end-diastolic volumes ( Figure 6A ) were similar to slightly higher and end-systolic volumes ( Figure 6B ) were higher for laboratory A compared with laboratory B. Dot-plot comparisons for LVEF and GLS 4CH measurements between ECLs are illustrated in the Online Appendix (Supplemental Figures 1 and 2 , available at www.onlinejase.com).
After reviewing individual results, readers identified three potential sources of interlaboratory variability, as follows: (1) single-beat measurements, (2) nonuniformity in image selection, and (3) endocardial border tracing conventions. Mitral inflow velocity differences were attributed to heterogeneity in the images selected for measurements, which was at the discretion of individual readers, and single-beat measurements. Heterogeneous image selection also contributed to variability in calculated LVEF and GLS 4CH measurements; however, laboratory-specific differences in endocardial border definition, particularly at end-systole, more consistently affected determination of LV volumes and the manually defined region of interest (ROI) for TomTec longitudinal strain analyses.
Readers reconciled sources of variability and repeated a limited set of measurements on all 25 echocardiograms. To address the impact on variability related to (1) single-beat measurements, readers remeasured mitral valve velocities and averaged measurements over three beats; (2) image selection heterogeneity, one laboratory B reader acted as an image selection control, aligning image selection for mitral valve velocity measurements with the laboratory A reader (the second laboratory B reader's image selection remained blinded and independent); and (3) endocardial border definition, readers remeasured GLS 4CH by selecting the speckle-tracking ROI at end-diastole, on the basis of previous results with LV volumes suggesting better interlaboratory agreement for end-diastolic endocardial border determinations.
On the second reproducibility testing, analysis of 400 pairwise comparisons for mitral valve E and A velocities (200 for each) among three readers across both ECLs demonstrated acceptable reproducibility for the minimum acceptable differences. Coverage probabilities improved for E (from 0.715 to 0.925) and A (from 0.760 to 0.810) velocities when results were the average of measurements taken over three beats; independent analysis of the 100 pairwise comparisons for the laboratory B reader aligned with the reader at laboratory A's image selection demonstrated further improvement in CP's for E (to 0.990) and A (to 0.940) velocities for the minimum acceptable differences. There was no improvement in reproducibility for GLS 4CH measurements when the strain ROI was defined using the endocardial border at end-diastole (CP = 0.775) versus end-systole (CP = 0.805). Comparisons of reproducibility from the initial and second assessments are shown in Table 4 .
DISCUSSION
Main Findings
Our main findings after directly comparing echocardiographic measurements obtained in patients with cancer between two academic ECLs are as follows: (1) reproducibility was strong within each ECL, confirming the utility and robustness of standard practices among ECL readers at Penn and DCRI, 26, 27 and (2) there was variability between ECLs for certain measurements, related to different ECL interpretations of guideline-recommended measurement conventions, suggesting a role for standardized application of measurement conventions across all ECLs.
Exploring the Variability of Measurements
Despite strong intralaboratory reproducibility, interlaboratory reproducibility results for mitral inflow velocities, quantitative LVEF, and GLS 4CH were less concordant. During subsequent reconciliation and retraining efforts, potential explanations for differences were considered by parameter, as follows: (1) mitral inflow velocities: single-beat measurements and interlaboratory heterogeneity in image and cardiac cycle selection likely accentuated differences due to inherent physiologic variability (e.g., respiratory changes); (2) LVEF: ventricular volumes were acceptably reproducible by pairwise comparisons, but divergent trends in volume measurements between ECLs likely affected LVEF estimations; and (3) GLS 4CH : laboratory-specific differences in endocardial border tracing conventions likely extended to how each ECL manually defined placement and thickness of the speckle-tracking ROI at end-systole for myocardial strain analyses. On reanalysis, reproducibility for mitral inflow velocities improved, demonstrating the importance of averaging multiple measurements to mitigate differences related to intrinsic physiologic variability and well-defined, prospectively determined image selection to generate homogeneous data points for measurement. Despite retraining, variability for GLS 4CH persisted, however, reflecting fundamental differences in how each ECL defined the endocardial borders that also affected quantitative LVEF measurements.
Importance of Precision in the Echocardiographic Assessment of Patients with Cancer
In cancer, at least a baseline assessment of LVEF is recommended for potentially cardiotoxic cancer therapies, 2 and serial assessments are mandated by the US Food and Drug Administration for certain agents, 28 with the primary goal to minimize risk for CTRCD. Echocardiography is commonly used to monitor cardiac function in clinical oncology practice; an LVEF that is low or has declined may prompt withdrawal or postponement of potentially curative cancer therapy. 29 Despite inherent variability of LVEF measurements related to dynamic biologic conditions and inconsistent image quality, echocardiography laboratories should endeavor to report consistently reproducible results 30 given the implications for cardiac and oncologic outcomes.
Alternative echocardiographic parameters of cardiac performance have recently emerged for the detection of early myocardial injury during cancer therapy. Echocardiography-derived measures of myocardial mechanics, including an impairment or relative decline in myocardial deformation by speckle-tracking longitudinal strain 13, 31 and changes in ventricular-arterial coupling, 26 have demonstrated predictive utility for LVEF decline and/or symptomatic heart failure. Novel modalities such as strain echocardiography may ultimately improve cardiovascular risk stratification and treatment of patients with cancer, although dependence on high-quality images, multiple evolving vendor acquisition and analysis platforms, 32 and uncertain optimal cutoff values for positive tests in cancer 1,2 also raise concerns.
Current State of Echocardiography for Identifying CTRCD
Current clinical investigations routinely use cardiac imaging to assess the potential of CTRCD. Oncology clinical trials assessing novel therapies often rely on LVEF assessment performed and interpreted at multiple clinical sites and often assessed visually. In general, cardiooncology investigations have not accounted for reproducibility concerns related to different image acquisition methods, variable image quality, and multiple observers that previous multicenter, multimodality cardiac imaging studies have reported. 8, 10 Failure to account for these issues has led to the inclusion of apparent ''outliers'' or ineligible subjects in clinical trials, potentially undermining the validity of results. 10, 11 In cardiology, the importance of a thoughtful, proactive approach to ensuring the validity of echocardiography results has been previously demonstrated by the Predictors of Response to Cardiac Resynchronization Therapy study, in which marked interlaboratory variability contributed to inconclusive results. 33 Studies that use echocardiography measurements for inclusion and/or end points now routinely use ECLs. 3 In this setting, large multicenter cardiovascular clinical trials have demonstrated that the standardized approach and consistency of an ECL minimizes measurement variability and improves the precision of study results, 9 with the potential also to enhance study outcomes. 12 
Implications of Findings for Echocardiography in Cardio-Oncology Research
To our knowledge, our study is the first to compare academic ECLs in the assessment of CTRCD parameters being studied in cardiooncology research. Strongly reproducible findings within the Penn and DCRI ECLs in our study confirm the value of a commitment in both laboratories to robust reproducibility and remediation processes to ensure temporal and reader validity 9, 26, 27 that is required
for high-quality quantitative echocardiographic research. 3 Our study also highlights, however, that a combination of small differences between ECLs in standard operating procedures and in the application of measurement conventions yielded slightly different ''assays'' for quantitative echocardiography data in each ECL, making interlaboratory reproducibility of certain echocardiography parameters potentially challenging. Going forward, the findings have reaffirmed the commitment of both ECLs to achieve consensus in the setting of multi-ECL studies and prompted consideration for creating a common set of images to serve as a potential reference standard across ECLs, similar to the international normalized ratio for prothrombin time ratio measurements.
Currently, our findings suggest the following: (1) use of a single ECL may be optimally suited to meet the needs of an individual clinical trial in minimizing variability and should similarly be considered for serial studies assessing a single drug or device; (2) in the absence of a single ECL, a strong commitment with adequate funding is needed to ensure quality and harmonization, including the possibility of several rounds of measurement testing and retesting; (3) results obtained from more than one ECL should not be combined unless proof of ''poolability'' is developed prospectively for parameters of interest, likely requiring extensive cross-training and process harmonization across ECLs; (4) comparability of results may be a more realistic goal, provided there is acceptable intralaboratory reproducibility and other aspects of studies are aligned; and (5) parameter cut points used in CTRCD criteria should be interpreted and determined cautiously, until these can be validated across multiple laboratories with additional attention to other potential sources of variability, such as vendor analysis and acquisition platforms. 
Core Lab Comparisons Using Other Cardiac Imaging Modalities
The importance of standardizing measurement conventions among different core labs has been similarly noted for cardiac imaging modalities outside echocardiography. 34, 35 In coronary angiography, clinical interpretations commonly rely on visual estimation of percentage stenosis, despite well-described intra-and interobserver variability. 36 Compared with visual estimations, quantitative coronary angiography improves the precision and accuracy of stenosis severity determinations. 37, 38 However, core labs had marked interlaboratory variability in quantitative coronary angiography of bifurcation stenosis due to software and measurement methodologic differences; subsequent analyses after aligning the core labs' software and methodology demonstrated improved interlaboratory variability and altered trial results. 34 In cardiac magnetic resonance, a comparison of LV volumes and mass measurements across seven core labs demonstrated small intrareader variability but considerable interreader and interlaboratory variability due to different contour drawing practices at each laboratory, highlighting the need to achieve consensus before multicenter analyses. 35 Although standardization can improve reproducibility among core labs, it is also an inherently challenging process that demands time, care, and attention to detail. Nevertheless, as accuracy is unattainable without precision, standardizing measurement conventions has the potential to positively affect the primary intent for all diagnostic testing (i.e., to guide patient management and reduce future clinical events). 39 
Implications of Findings for Echocardiography in Clinical Cardio-Oncology
Reproducibility findings between ECLs at Penn and DCRI may extend to clinical laboratories that quantify echocardiographic parameters during cardiac monitoring of patients with cancer. Guidelines 2 and prior studies 13, 31 have emphasized the importance of changes in LVEF and GLS for identifying CTRCD. Our study suggests that comparing quantitative echocardiographic measurements across laboratories should be considered in a similar context to comparing blood biomarker (e.g., troponins, natriuretic peptides) results across institutions with different measurement assays and reference ranges. Accordingly, comparing small changes across readers and laboratories should be performed cautiously. The ideal clinical environment for cardio-oncology patients likely includes serial studies with a consistent vendor acquisition and analysis platform and sonographer or reader in a single laboratory that uses continuous quality monitoring and improvement processes to optimize image acquisition quality as well as robust reproducibility testing and remediation processes to ensure temporal and interreader validity of echocardiographic data.
Limitations
Quantitative echocardiography studies are generally limited by a lack of established standards that define acceptable reproducibility for individual parameters. For instance, the absence of an external reference ''gold'' standard technique such as cardiac magnetic resonance imaging for identifying the LV endocardial border against which to compare each ECL's tracing conventions limited the potential of harmonization and retraining efforts for improving interlaboratory reproducibility for LVEF and GLS 4CH results. Nevertheless, our study sought to be one of the first to perform a detailed comparison between ECLs. Although our findings respective to parameters of LV systolic function may be affected by using a single view assessment, an ECL study from a major cardiovascular trial demonstrated highly correlated single-plane and biplane LV volumes, 10 and a recent intervendor study demonstrated that longitudinal strain derived from the four-chamber view alone was strongly correlated with values derived from all three apical views. 25 In addition, we could not assess the variability of GLS calculated using endocardial length in diastole and systole, as has recently been recommended by the American Society of Echocardiography 16 ; software adapted to measure strain by endocardial length was not available at the time of our study.
Our study had other important limitations. First, harmonization efforts that included several group reads incorporating multiple readers, measurements, and iterations were time consuming. During multiple rounds of training, the time commitment for some interventions (e.g., averaging multiple beats and controlling image selection for Doppler measurements) was more feasible than for others (e.g., reconciling fundamental interlaboratory differences in endocardial border tracing conventions), limiting our ability to improve interlaboratory reproducibility for LV systolic functional parameters. Future studies in which ECLs try to comprehensively align measurements will require adequate time and funding to optimize corrective actions.
Second, a relatively small size of 25 echocardiograms was tested for reproducibility, although this number is similar to other reproducibility studies 8, 27, 30 and allowed large numbers of pairwise comparisons, making it statistically robust.
Third, echocardiograms selected for analysis were previously acquired in the clinical laboratories at both institutions; measurements were limited to noncontrast, 2D images for consistency, although previous studies have reported that contrast administration did not improve reproducibility of serial 2D echocardiograms in patients with breast cancer. 4 Fourth, the ECLs used different software to make 2D and Doppler measurements (Penn, TomTec; DCRI, Digisonics), potentially affecting reproducibility for these parameters.
Fifth, although lack of clinical data limits the generalizability of our findings, it also minimized potential bias affecting ECL analyses. Sources of variability have been described with strain imaging. 32 Our GLS reproducibility findings in the context of ECL commonalities across vendor acquisition platform, image acquisition frame rates, and strain analysis software are not necessarily analogous to laboratory settings in which echocardiography studies acquired and analyzed on multiple platforms are being compared.
Finally, our study was intended to define reliability and reproducibility between ECLs rather than validate the diagnostic accuracy of measurements; the absence of a reference standard to validate accuracy limited the potential for reproducibility assessments among patient subgroups with suggestion of impaired LVEF and GLS 4CH .
CONCLUSIONS
High-quality quantitative echocardiography research requires a commitment to robust reproducibility and remediation processes with demonstrated good results. Low variability or uniformity in echocardiography measurements within or across laboratories cannot be assumed; interlaboratory agreement may be difficult even among academic ECLs that are highly internally reproducible. Comparisons of small changes in LVEF and GLS across readers and laboratories should be performed cautiously. Research designs should acknowledge these findings and consider a single ECL for individual clinical trials and series of studies testing a single drug or device, while results of serial clinical studies should be interpreted accordingly.
SUPPLEMENTARY DATA
Supplementary data related to this article can be found online at https://doi.org/10.1016/j.echo.2017.11.018. 4CH reproducibility results between ECLs. Interlaboratory pairwise comparisons on testing of GLS 4CH (CP = 0.805) illustrate a trend toward positive measurement differences for laboratory A versus laboratory B consistent with more negative (higher absolute) GLS 4CH values at laboratory B. GLS 4CH was determined in the apical four-chamber view. Red dots indicate reader pairs exceeding the minimum acceptable difference of 4%; green dots indicate those pairs within the acceptable difference. A, Laboratory A; B, laboratory B; +GLS, more positive GLS 4CH values; ÀGLS, more negative GLS 4CH value (range of GLS 4CH values depicted is referenced to laboratory A results).
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